ReviewAmerican journal of clinical dermatology2023
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis.
Review in American journal of clinical dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Article
- The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy.Dermatopathology (Basel, Switzerland) · 2026Review
- Secretome as a novel regenerative strategy for atopic dermatitis: a comprehensive review.Stem cell research & therapy · 2026Review
- Efficacy of Lebrikizumab on Pruritus: A Narrative Review.Advances in therapy · 2026Review
- Retrospective Analysis of Lebrikizumab in the Management of Atopic Dermatitis: Insights from Real-World Practice.Dermatology and therapy · 2026Article
- Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study.Dermatology and therapy · 2025Article
- Atopic dermatitis: diagnosis, molecular pathogenesis, and therapeutics.Molecular biomedicine · 2025Review
- Atopic Dermatitis Management: from Conventional Therapies to Biomarker-Driven Treatment Approaches.Biomolecules & therapeutics · 2025Review
- Type 2 Inflammation and Its Role in Dermatologic Diseases.International journal of dermatology · 2025Review
- A Clinician's Guide to Dupilumab-related Ocular Surface Disease.The Journal of clinical and aesthetic dermatology · 2025Article
- Article
- Monoclonal Antibodies: Current Advancements and Future Potential for Atopic Dermatitis Therapy.Current pharmaceutical biotechnology · 2025Review
- Hypothesis: platelet-rich plasma as an adjunct therapy for eczema targeting inflammation, skin barrier repair, and chronic recurrence.Frontiers in immunology · 2025Article
- IL-13 inhibition in the treatment of atopic dermatitis - new and emerging biologic agents.The Journal of international medical research · 2024Review
- Lebrikizumab: First Approval.Drugs · 2024Review
- Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a common, heterogeneous, inflammatory skin disorder characterized by chronic or relapsing eczematous lesions with intense pruritus and discomfort. Affected patients often experience significant impairment in their quality of life, and the treatment of moderate-to-severe AD forms remains challenging. In the past few decades, increasing knowledge on the AD pathogenesis has driven the development of novel targeted therapies. Interleukin (IL)-13 plays a central and pleiotropic role in AD pathogenesis, contributing directly or indirectly to epidermal barrier disfunction, type-2 inflammation, dysbiosis, fibrosis, and itch response. For this reason, agents selectively targeting IL-13, such as lebrikizumab, emerged as a potential therapy for AD. This article reviews the current evidence about lebrikizumab in the management of AD. The phase II and phase III trials seem to corroborate efficacy of lebrikizumab in the treatment of moderate-to-severe AD, as shown by significant improvement of Eczema Area and Severity Index, body surface area, and pruritus scores. Also, lebrikizumab demonstrated favorable safety and tolerability profiles, with the majority of patients experiencing no significant adverse events. Lebrikizumab seems to be a promising emerging targeted biological agent for patients with moderate-to-severe AD. More data on the long-term efficacy and safety, head-to-head comparisons with other agents, and real-world evidence will help to clarify its place in therapy in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.